Trending...
- New Rochelle: Hudson Park Children's Greenhouse Presents the 2nd Annual "Winter Train Show"
- Richard "Richie B" Burgess Teams up with New York Based Media Networks
- New Rochelle: Registration Begins for 2025 Citizen Police Academy
JUPITER, Fla. - Nyenta -- First Choice Neurology, the largest neurology group in the United States, is set to make medical history next week as Dr. Jennifer Buczyner and Dr. Jeff Gelblum are among the first physicians in the country to administer the newly FDA-approved drug Kisunla to patients. This groundbreaking development marks a significant milestone in neurological care, offering new hope to patients battling a range of neurological conditions.
Kisunla, by Eli Lilly represents a promising advancement in neurology, specifically targeting Alzheimer's disease and dementia. Kisunla is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Dr. Jeff Gelblum, Neurologist in Aventura, Florida, has significant experience using anti-amyloid infusion therapy for his patients with mild cognitive impairment and mild Alzheimer's disease. He has many patients taking Leqembi with which was FDA approved in July 2023.
He is also looking forward to using Kisunla in his patients for the same conditions and differentiates the two products, accordingly: "The two drugs target the same endpoint, reduction of brain amyloid plaque which is a marker of Alzheimer's disease. Leqembi is given twice a month for a full 18 months. Kisunla is once a month and may be able to be stopped as soon as six months, based upon clearance of amyloid plaque on a follow up brain PET scan. Leqembi has a lower incidence of side effects of brain swelling and bleeding."
More on Nyenta.com
Gelblum notes, "that a patient who is unable to go for twice monthly infusions and eager to possibly conclude treatment in as soon as six months, who can also assume the greater safety risk, would be a good candidate for the new treatment."
Dr. Jennifer Buczyner, Neurologist in Jupiter, Florida said, "The approval of Kisunla offers another opportunity for patients with mild cognitive impairment or mild dementia and brings those with mild cognitive impairment to early medical attention. In studies, Kisunla slowed cognitive and functional decline by up to 35 percent compared to placebo at 18 months and reduced patients' risk of progressing to the next clinical stage of disease by up to 39 percent. We at First Choice Neurology are very excited to offer anti-amyloid therapies to our South Florida communities."
The introduction of Kisunla underscores First Choice Neurology's commitment to pioneering treatments that transform the landscape of neurological care. As the first physicians in the United States to administer Kisunla, Dr. Gelblum and Dr. Buczyner exemplify the group's leadership in bringing cutting-edge therapies to patients.
More on Nyenta.com
About First Choice Neurology
First Choice Neurology is the largest neurology group in the United States with over 60 Care Centers in multiple Florida counties and services at more than 45 major hospitals. The group provides comprehensive neurological care for patients with a wide range of conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson's disease, sleep disorders, strokes, traumatic brain injuries, and more. With a commitment to innovation and patient-centered care, First Choice Neurology continues to lead advancements in neurological treatments nationwide.
For more information about Kisunla and First Choice Neurology, visit fcneurology.com
Kisunla, by Eli Lilly represents a promising advancement in neurology, specifically targeting Alzheimer's disease and dementia. Kisunla is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Dr. Jeff Gelblum, Neurologist in Aventura, Florida, has significant experience using anti-amyloid infusion therapy for his patients with mild cognitive impairment and mild Alzheimer's disease. He has many patients taking Leqembi with which was FDA approved in July 2023.
He is also looking forward to using Kisunla in his patients for the same conditions and differentiates the two products, accordingly: "The two drugs target the same endpoint, reduction of brain amyloid plaque which is a marker of Alzheimer's disease. Leqembi is given twice a month for a full 18 months. Kisunla is once a month and may be able to be stopped as soon as six months, based upon clearance of amyloid plaque on a follow up brain PET scan. Leqembi has a lower incidence of side effects of brain swelling and bleeding."
More on Nyenta.com
- Bit Digital, Inc. Announces Monthly Production Update for January 2025
- Bad Boy Is in Turmoil! What was Behind the Scenes of the Life of Biggie Smalls and Music Industry
- Js Art Gallery: A New International Art Space Promoting Unity Through Art
- Global Mobile Software, LLC Announces Sponsorship of Max Metcalfe, Goalkeeper at Stockport County FC
- New Rochelle: Update: Arrests Made in Connection with Deceased Juvenile Found on Washington Ave and Charles St
Gelblum notes, "that a patient who is unable to go for twice monthly infusions and eager to possibly conclude treatment in as soon as six months, who can also assume the greater safety risk, would be a good candidate for the new treatment."
Dr. Jennifer Buczyner, Neurologist in Jupiter, Florida said, "The approval of Kisunla offers another opportunity for patients with mild cognitive impairment or mild dementia and brings those with mild cognitive impairment to early medical attention. In studies, Kisunla slowed cognitive and functional decline by up to 35 percent compared to placebo at 18 months and reduced patients' risk of progressing to the next clinical stage of disease by up to 39 percent. We at First Choice Neurology are very excited to offer anti-amyloid therapies to our South Florida communities."
The introduction of Kisunla underscores First Choice Neurology's commitment to pioneering treatments that transform the landscape of neurological care. As the first physicians in the United States to administer Kisunla, Dr. Gelblum and Dr. Buczyner exemplify the group's leadership in bringing cutting-edge therapies to patients.
More on Nyenta.com
- Invenio IT Now Offers Dark Web ID Monitoring to Enhance Data Protection Services
- Kansas City Edges Philadelphia On Mahomes TD Pass With 0:15 Left In Strat-O-Matic Simulation
- SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Newmont
- Talent Concierge Artists Agency Welcomes Emily Williams to Its Elite Roster of Talent
- Harlem Fine Arts Show Returns for 17th Year, Celebrating the African Diaspora
About First Choice Neurology
First Choice Neurology is the largest neurology group in the United States with over 60 Care Centers in multiple Florida counties and services at more than 45 major hospitals. The group provides comprehensive neurological care for patients with a wide range of conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson's disease, sleep disorders, strokes, traumatic brain injuries, and more. With a commitment to innovation and patient-centered care, First Choice Neurology continues to lead advancements in neurological treatments nationwide.
For more information about Kisunla and First Choice Neurology, visit fcneurology.com
Source: First Choice Neurology
0 Comments
Latest on Nyenta.com
- Your Life Is About to Get More Expensive: How Tariffs Work
- Cassio Domingues Neto Joins the Icla da Silva Foundation Board of Trustees
- White Plains Artist Erwin Ong Featured in Grumpy Bert Red Envelope Show at Harman Contemporary (NYC)
- Ton-Up Records Takes Aim With Toy Machine Gun
- New Rochelle: Deceased Person Found - Washington Ave and Charles St
- $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Altus Power, Inc. - AMPS
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025
- Bulge Bracket Bank Loyalty Programs Continue to Offer CourMed Private Client Health & Wellness
- Wall Street analyst affirms Rochester's strong credit rating
- Gold Coast Health Plan Distributes $225,000 for Fire Relief and Preparedness Efforts
- B2B Lead Generation Solutions: Empowering Your Sales Pipeline
- The Dallas Group of America, Inc. Celebrates the 50th Anniversary of Landmark Facility
- Centers Health Care Honored with American Heart Association Achievement Award for Cardiovascular Care Excellence
- Invenio IT Introduces Graphus Email Protection to Strengthen Client Security
- Kelvin Emtech and Colm Engineering Unveil Strategic Joint Venture, to Boost Data Center and Building M&E Capabilities
- Preeminent SEC Enforcement Lawyer Joins Latham in New York
- Legal-Bay Pre-Settlement Lawsuit Funding Reports Increase in Motor Vehicle Accident Claims
- Women Wisdom & Wine Inaugural Retreat Experience: A Transformative Journey for Women in the Poconos
- Why Regular Appliance Repair Is a Smart Investment for NYC Homeowners
- InterContinental New York Times Square by IHG, celebrates the Month of Love with Suite Accommodation Special Offers and Valentine's Day Activations including a Moët Popup Bar, Jazz Trio Evenings and Yoga Classes for couples